Search the Newsreel

Armistice Capital (RPID) discloses 3.33M-share position in Rapid Micro Biosystems

Armistice Capital, LLC and Steven Boyd have disclosed a 7.29% stake in Rapid Micro Biosystems, Inc. (RPID), amounting to 3,328,000 shares of Class A common stock. All voting and dispositive power over these shares is shared, with Armistice Capital acting as the investment manager …

TuHURA Biosciences, Inc. - Common Stock (HURA) Stock Price, News, Quote & History

This article provides a comprehensive overview of TuHURA Biosciences, Inc. (HURA) stock, including its current price, market data, and recent news. It highlights the company's focus on advancing biotechnology solutions, particularly in developing therapies and diagnostic tools. The news section features updates on their …

Armistice Capital (RKDA holder) discloses 9.99% beneficial stake in Arcadia Biosciences

Armistice Capital, LLC and Steven Boyd have reported a 9.99% beneficial ownership stake in Arcadia Biosciences, Inc., totaling 267,392 shares. These shares are held by Armistice Capital Master Fund Ltd., with Armistice Capital acting as the investment manager, exercising shared voting and dispositive power. …

Form 8K Skye Bioscience Inc For: 14 August By Investing.com

This article reports that Skye Bioscience Inc. filed a Form 8K on August 14. The filing is a standard disclosure document used by public companies to announce major events that shareholders should know about. The article provides no further details on the content of …

TuHURA Biosciences Highlights Phase III IFx Push, AML Trial Plans at Canaccord

TuHURA Biosciences presented its late-stage immuno-oncology pipeline at the Canaccord Genuity Growth Conference, detailing a Phase III study of IFx in Merkel cell carcinoma, a planned AML trial for its VISTA-inhibiting antibody, and preclinical work on immune-modulating antibody-drug conjugates. The company aims to address …

GUFICBIO: Q1 FY27 saw strong profit growth and a major international expansion into the Philippines

Harmony Biosciences Highlights Record WAKIX Growth, Advances Orexin and Epilepsy Pipeline

Harmony Biosciences reported record quarterly growth for its narcolepsy treatment WAKIX, which supports further investment in its pipeline. The company is advancing BP-205, an orexin 2 receptor agonist, with promising early data and plans for multiple Phase II studies. Additionally, Harmony is progressing Phase …

TuHURA Biosciences Q2 Results: EPS beats estimate, losses narrow 33% YoY

Caribou Biosciences, Inc. Stock 12‑Month Price Target Cut to $11.86, Implies 636% Upside

Analysts have cut the 12-month average price target for Caribou Biosciences, Inc. stock from $12 to $11.86, with individual forecasts ranging from $4 to $32 per share. Despite the slight reduction in the average target, this still implies a significant 636% potential upside based …

Alamar Biosciences (ALMR) Stock Price Jumps As Margin Gains Meet Loss Pressure

Alamar Biosciences (ALMR) stock surged 30.7% after its first post-IPO quarter, despite reporting a net loss of US$13.2m. The company achieved US$29.4m in revenue and a record 60% gross margin, driven by strong demand for consumables and instruments. While bulls highlight top-line growth and …

Skye Bioscience to Acquire Redx; Secures $67.9M Financing and $22M Equity Line

Skye Bioscience is set to acquire Redx through a UK court-sanctioned scheme of arrangement, backed by a significant financing package. The deal includes a $67.9 million equity financing (potentially rising to $72.9 million), a $22.0 million equity line, and a $5.0 million warrant with …

Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in Financings

Skye Bioscience and Redx Pharma have announced a definitive transaction agreement, forming a combined company named Fibrx Therapeutics, which will focus on developing novel small molecule medicines for fibrotic diseases. This merger is supported by approximately $125 million in financings, including a PIPE financing …

Forte Biosciences earnings on deck as $2.2 billion argenx deal nears

Forte Biosciences is set to report its second-quarter earnings, which are expected to be largely a formality as the company awaits the completion of its $2.2 billion acquisition by argenx. Analysts anticipate a loss of $1.01 per share on zero revenue for Forte. The …

Artelo Biosciences (ARTL) major holder reports 0% ownership in new 13G/A

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G/A for Artelo Biosciences (ARTL), reporting that they no longer beneficially own any common stock in the company. As of June 30, 2026, their ownership stake is 0 shares, representing 0.0% of the …

Rapid Micro Biosystems (RPID) Q2 2026 Earnings Call Transcript

Skye Bioscience (NASDAQ: SKYE) exits obesity trial, pursues Redx merger and $100M+ funding

Skye Bioscience is discontinuing its nimacimab obesity program and pursuing a merger with Redx Pharma to form Fibrx Therapeutics, Inc. This strategic shift addresses significant financial strains, as evidenced by a $23.3 million net loss and a substantial doubt about its ability to continue …

Skye Bioscience, Inc. 2026: Revenue $178.2K, EPS ($0.27) — 10-Q Summary

Skye Bioscience, Inc. reported its 2026 quarterly results, showing revenue of $178.2K and a net loss of ($10.79M), leading to a diluted loss per share of ($0.27), which is an improvement over the prior year. The company also announced the termination of its CBeyond …

Arcadia Biosciences (RKDA) Announces Second Quarter and First Half 2026 Financial Results and Business Highlights

Arcadia Biosciences (RKDA) announced its second quarter and first half 2026 financial results, highlighting a significant reduction in cash used in operating activities and a strong cash balance. The company reported flat sales for Q2 2026 due to inventory and shipping issues, which have …

Form 8K TuHURA Biosciences Inc For: 14 August By Investing.com

This article reports that TuHURA Biosciences Inc. filed a Form 8K on August 14. The filing is a standard regulatory disclosure and contains no further details within this brief report, beyond mentioning the company's stock symbol, HURA, which was up 7.39% at the time …

Twist Bioscience (TWST): EdgePoint discloses 4.21% beneficial stake in amended 13G

EdgePoint Investment Group Inc. has filed an amended Schedule 13G, disclosing a 4.21% beneficial ownership stake in Twist Bioscience Corp (TWST), totaling 2,521,635 shares as of June 30, 2026. The filing indicates EdgePoint acts as an investment manager for various funds that directly own …

HC Wainwright Has Bearish Estimate for DTIL Q3 Earnings

Deep Track Capital reports 3.64% MBX Biosciences (MBX) stake in 13G/A

Deep Track Capital, LP, along with Deep Track Biotechnology Master Fund, Ltd., and David Kroin, has filed an amended Schedule 13G/A disclosing a beneficial ownership of 3.64% in MBX Biosciences (MBX). This group collectively holds 1,732,569 shares of common stock as of June 30, …

Why Microbix Biosystems Inc. stock plummeted yesterday

Farallon group trims Tyra Biosciences (TYRA) holdings to 6,000 shares, 0% stake

Farallon Capital Management, L.L.C., along with several related investment entities and individuals, has filed an Amendment No. 2 to a Schedule 13G/A, reporting beneficial ownership of 6,000 shares of Tyra Biosciences (TYRA) common stock, which constitutes a 0% stake as of June 30, 2026. …

TuHURA Bios reports Q2 2026: $1.0M cash, R&D $6.6M, $50M credit facility extends runway

TuHURA Bios reported its Q2 2026 results, showing $1.0 million in cash and cash equivalents and R&D expenses of $6.6 million. The company secured a new $50 million term credit facility from its largest shareholder, extending its cash runway into 2028. This credit facility …

Cutting-edge drug quells insatiable desire to eat. Experts warn it could be tied to deaths

Neurocrine's drug, Vykat XR, designed to treat the insatiable appetite associated with Prader-Willi Syndrome (PWS), is facing safety warnings following seven deaths. Patient organizations and doctors are calling for more research into the drug's safety, emphasizing that PWS patients often have multiple other health …

Rapid Micro Biosystems (RPID) major holder Bain updates Schedule 13G/A stake

Bain Capital Life Sciences-affiliated funds have updated their stake in Rapid Micro Biosystems (RPID) Class A common stock through a Schedule 13G/A filing. As of June 30, 2026, Bain Capital Life Sciences Fund, L.P. beneficially owned 16.8% of outstanding shares, while BCIP Life Sciences …

Balyasny Asset Management (CLRB) discloses 9.99% Cellectar stake via stock and warrants

Balyasny Asset Management and affiliated entities have disclosed a 9.99% beneficial ownership stake in Cellectar Biosciences (CLRB) through a Schedule 13G SEC filing. This stake comprises 220,000 common shares and 578,382 shares issuable upon the exercise of warrants, all held under a 9.99% Beneficial …

Aura Biosciences (AURA): Long Focus Capital reports 4.9% ownership

Long Focus Capital Management, LLC and John Helmers have reported a 4.9% beneficial ownership stake in Aura Biosciences, Inc. (AURA) through a Schedule 13G filing. As of June 30, 2026, they beneficially owned 5,119,582 shares of common stock, with shared voting and dispositive power. …

Wedge Capital Management L L P NC Purchases New Stake in Pacira BioSciences, Inc. $PCRX

Wedge Capital Management L L P NC has acquired a new stake in Pacira BioSciences, Inc. (NASDAQ:PCRX), purchasing 94,554 shares valued at approximately $2.4 million. This acquisition makes Wedge Capital a 0.24% owner of the company, which reports 99.73% institutional ownership. Pacira BioSciences recently …

Inhibrx Biosciences, Inc. (NASDAQ:INBX) Given Consensus Recommendation of "Hold" by Brokerages

Inhibrx Biosciences (NASDAQ:INBX) has received a consensus "Hold" recommendation from brokerages, with an average 12-month price target of $150.00. The company recently reported a quarterly EPS of -$2.34, missing analyst estimates, and institutional investors now own 82.46% of the stock. BlackRock Inc. notably acquired …

Arcus Biosciences, Inc. Stock 12‑Month Price Target Raised to $38.82, Implies 35% Upside

Arcus Biosciences, Inc. (RCUS) has seen its average 12-month price target raised from $38.33 to $38.82 by 11 analysts, with forecasts ranging from $23 to $47 per share. This new target implies a potential upside of approximately 35% from its August 13 closing price. …

Emergent Biosolutions (EBS) Earnings Date and Reports 2026 $EBS

Alamar Biosciences: The Content Flywheel Is More Valuable Than The Instrument

Barclays Maintains Forte Biosciences(FBRX.US) With Hold Rating, Maintains Target Price $77

Barclays has reiterated its 'Hold' rating on Forte Biosciences (FBRX.US) and maintained its target price at $77. This indicates that the financial institution sees the stock performing in line with the broader market and expects its value to remain stable at the specified price …

Daré Bioscience targets Ovaprene top-line data in 2027 as it plans DARE to PLAY dispensing this quarter

Earnings Call Insights: Daré Bioscience (DARE) Q2 2026 MANAGEMENT VIEW * "In June, we launched Flora Sync LF5, the first product in our DARE to RESTORE line." (CEO, President, Principal Financial Officer, Secretary & Director Sabrina Johnson) * "At the same time, we continued …